Novo Nordisk on Friday raised its outlook for its full-year sales and operating profit for the third time this year, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States.
Novo's shares jumped more than 5% to a record-high on the news, but pared gains to trade 2.5% higher at 1422 GMT.
It raised its full-year outlook for growth in earnings before interest and tax to 40-46% from the previous 31-37% range. The new sales outlook for this year primarily reflects higher expectations for profits related to sales of Ozempic and Wegovy in the United States.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk raises full-year guidance again as US sales of Wegovy, Ozempic flyNovo Nordisk (NOVOb.CO) on Friday raised its outlook for its full-year sales and operating profit for the third time this year, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States.
Read more »
Novo Nordisk Raises Sales Outlook on Soaring Demand for Ozempic and WegovyNovo Nordisk now expects 2023 sales growth of between 32% and 38%.
Read more »
Novo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surgeNovo Nordisk gains after boosting 2023 outlook on Ozempic, Wegovy sales surge
Read more »
Novo Nordisk boosts sales and profit outlook, buoyed by Ozempic and WegovyEleanor Laise is a healthcare reporter for MarketWatch and is based in Washington.
Read more »
Novo Nordisk hikes outlook on soaring demand for Wegovy, OzempicNovo Nordisk's forecast only confirms the frenzy for Wegovy and Ozempic, which patients seek for their ability to help them lose significant weight over time.
Read more »
Novo Nordisk warns online offers of fake Ozempic, Wegovy are risingNovo Nordisk (NOVOb.CO) warned on Thursday of a surge in counterfeit versions of its weight-loss drug Wegovy and diabetes drug Ozempic offered online, as German authorities gave more details of complex European trades in a fake drug case.
Read more »